Effectiveness of and Satisfaction With a Pharmacist-managed Travel Medicine Clinic

Travel Medicine Clinical Trial

Official title:

Determining the Clinical Effectiveness and Patient Satisfaction of a Pharmacist-managed Travel Medicine Clinic Under an Expanded Scope of Practice

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02625129
• Other study ID #: 21080
• Status: Completed
• Phase: N/A
• First received: November 25, 2015
• Last updated: January 17, 2018
• Start date: February 2016
• Est. completion date: April 2017

Study information

• Verified date: January 2018
• Source: University of Waterloo
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study will evaluate the clinical effectiveness of, and patient satisfaction with, pre-travel consultations provided by a pharmacist with specialty training in travel medicine and the authorization to prescribe medications and administer vaccinations.

Description:

The study will be conducted at the Travel Health Network, a full-service travel medicine clinic located in St. Albert, Alberta. Care will be provided by a pharmacist with a specialized practice in travel medicine, authorization to prescribe vaccines and prescription drugs, and authorization to administer vaccines by injection.

The study will be a prospective mixed-methods cohort study, describing patients receiving care from a pharmacist-managed travel medicine clinic and their travel health needs, and evaluating their adherence to recommended vaccines and oral therapies, satisfaction with the care provided, and their health status and management of health issues arising while travelling. Chart reviews will elicit descriptive quantitative data related to patients' travel medicine needs and adherence to recommended vaccinations and oral pharmacotherapy, followed by surveys containing open-ended qualitative questions to elicit overall patient satisfaction and the management of any health issues encountered during travel. Due to the nature of the study involving patients presenting to the clinic for a consultation, neither a control group nor blinding is possible.

A convenience sample of 100 subjects will be enrolled.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 103
• Est. completion date: April 2017
• Est. primary completion date: April 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Receiving a pre-travel consultation at the Travel Health Network clinic in St. Albert, Alberta, Canada

Exclusion Criteria:

• Travellers with an expected return date after September 1, 2016

• Those receiving consultations as part of a group with the same itinerary (e.g., families, group vacations) will be asked to identify one member to participate in order to minimize repetition among participants.

Related Conditions & MeSH terms

• Travel Medicine

Intervention

Other:
• Pharmacist-provided travel care
Subjects will receive a pre-travel consultation from a pharmacist with specialty training in travel medicine, and with authorization to prescribe medications and vaccines and administer injections

Locations

Country	Name	City	State
Canada	Travel Health Network	St. Albert	Alberta

Sponsors (3)

Lead Sponsor	Collaborator
University of Waterloo	Travel Health Network, University of Mississippi Medical Center

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The proportion of recommended pre-travel vaccinations administered before departure according to chart review	From date of pre-travel consultation until the date of travel departure according to participant's planned itinerary, assessed up to September 2016.	Up to 7 months.
Primary	The proportion of recommended pre-travel oral pharmacotherapies dispensed before departure by a community pharmacy according to electronic health record	From date of pre-travel consultation until the date of travel departure according to participant's planned itinerary, assessed up to September 2016.	Up to 7 months.
Secondary	Average satisfaction (along 1-5 scale) with care provided elicited through an online survey post-travel		1 week following return from travel according to participant's planned itinerary
Secondary	Frequency of reason(s) for declining any recommended vaccines or medications according to participant self-report through an online survey	Response options: didn't feel I was at risk, cost, concern about vaccine ingredients or safety, other (specify)	1 week following return from travel according to participant's planned itinerary
Secondary	Number of reports of any health issues over the course of travel according to participant self-report through an online survey	Response options: Traveller's diarrhea, Altitude sickness, Malaria, Fever (Dengue, Chikungunya), Respiratory illness, Other (specify)	1 week following return from travel according to participant's planned itinerary
Secondary	Frequency of management strategies of any health issues over the course of travel according to participant self-report through an online survey	Response options: Nothing - it went away on its own, Took a non-prescription medication I had purchased before departure, Took a non-prescription medication I purchased while travelling, Called or emailed the Travel Health Network for advice, Searched the internet for guidance on how to manage it, Saw a physician while travelling, Saw a physician upon returning home, Other (specify)	1 week following return from travel according to participant's planned itinerary